Keywords: palatin, enrolls, patients, pt-141, trials, sexual, dysfunction
Palatin enrolls patients in PT-141 trials for sexual dysfunction
Article | 17 January 2005
US firm Palatin Technologies says it has completed enrollment in separate Phase IIclinical trials evaluating PT-141 in patients experiencing female ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
